8 citations
,
October 2023 in “Frontiers in Immunology” Certain cytokines may cause or be affected by immune skin diseases, suggesting possible new treatments.
2 citations
,
July 2014 in “Our Dermatology Online” Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.
June 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Children with frequent severe infections and low antibodies should be checked for immune deficiencies.
March 2026 in “Photodermatology Photoimmunology & Photomedicine” This study examined UV protection habits and preferences among 120 participants with cutaneous immune-mediated inflammatory diseases (IMIDs) and healthy controls. It found that daily photoprotection was practiced by 40% of participants, with vitiligo patients showing the highest adherence at 55%. Hat use was notably higher among alopecia areata patients (40%). Most participants (95%) used SPF > 15, with creams being the preferred format. Vitiligo patients also had the highest compliance with disease-specific UV protection recommendations (70%). The study highlights the importance of educating patients with IMIDs on tailored UV protection to enhance compliance and disease management.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
9 citations
,
December 2020 in “Dermatologic Therapy” Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
April 2017 in “Journal of Investigative Dermatology” Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
28 citations
,
March 2018 in “Archives of Dermatological Research” 
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
9 citations
,
April 1993 in “Journal of the National Cancer Institute” Interleukin-2 treatment improved hair growth, sexual function, and reduced fungal infection in a patient with thymoma-related symptoms.
25 citations
,
July 1994 in “Archives of Dermatology” A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.
April 2023 in “Journal of Investigative Dermatology” IL-9/IL-9R signaling can negatively affect human hair growth and may be a target for treating hair loss conditions.
March 2023 in “Clinical, cosmetic and investigational dermatology” IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
September 2022 in “The American Journal of Dermatopathology” Blocking IL-17 might help treat the hair loss condition Lichen planopilaris.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
27 citations
,
September 1992 in “The Lancet” ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.
ILC1-like cells may contribute to hair loss in alopecia areata.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
5 citations
,
January 2019 in “International Journal of STD & AIDS” An HIV patient with IRIS had rare syphilis symptoms affecting skin, eyes, and nerves.
May 2023 in “Elsevier eBooks” Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.